UNSPSC 51162015: Butabarbital/guaifenesin/pseudoephedrine/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162015 Butabarbital/guaifenesin/pseudoephedrine/theophylline is a Commodity code for which state and local governments' recent solicitations show minimal direct activity aligned with the code's nominal pharmaceutical composition. The recent opportunities tagged to this code are pursuing emergency medical countermeasures (naloxone), on-site employer pharmacy services, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which center on the butabarbital/guaifenesin/pseudoephedrine/theophylline combination the code names. The issuing bodies span county health departments (Seminole County, Florida), county employer group health plans (Hall County, Georgia), state pharmacy benefit programs (Texas HHS Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participating jurisdictions). The mismatch between the code's specific drug combination and the actual procurement scope suggests this code shows little relevant recent activity for vendors specializing in the named pharmaceutical formulation.

Recent opportunities under this code classification include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida); Hall County's RFQ/P for on-site pharmacy services at the county health center serving 3,005 covered individuals (due June 4, 2026); Texas HHS Commission's RFI regarding direct-to-manufacturer prescription programs (issued April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (due March 26, 2026, with contract effectiveness July 1, 2026). Geographic activity spans Florida, Georgia, Texas, and Minnesota, with MMCAP's cooperative vehicle extending to Oregon and other member jurisdictions. The divergence between the code's chemical specificity and the broad pharmaceutical procurement activity it currently captures suggests reviewing the code's assignment with the issuing bodies' procurement staff before pursuing opportunities under this classification.